Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Enlivex Therapeutics Ltd. | Allocetra | Sepsis | Phase 2 | Ongoing | Intravenous | N/A |
| Ensysce Biosciences Inc. | PF614-301 | Moderate to Severe Pain after Abdominoplasty | Phase 3 | Enrollment Initiation | oral | Opioid Analgesic |
| Ensysce Biosciences Inc. | PF614-102 | Severe pain | Phase 3 | Enrollment Initiation | oral | Opioid Analgesic |
| Ensysce Biosciences Inc. | PF614-201 | Severe Pain Relief | Phase 3 | Ongoing | Oral | Opioid Analgesic |
| Ensysce Biosciences Inc. | BupiZenge | Head and neck cancer | Phase 3 | Trial Planned | Buccal | Oncology |
| Entero Therapeutics Inc Com Par $0.0001 (New) | Niclosamide (FW-420) - (PASSPORT) | Colitis and diarrhea in oncology patients | Phase 2a | Oral | Oncology | |
| Entero Therapeutics Inc Com Par $0.0001 (New) | FW-UP (niclosamide) | Ulcerative Proctitis (UP) and Ulcerative Proctosigmoiditis (UPS) | Phase 2b | oral | Gastroenterology | |
| Entero Therapeutics Inc Com Par $0.0001 (New) | MS1819-SD | Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency | Phase 2 | oral | Gastroenterology |
